Docket No.: HITACHI.055CP2



INFORMATION DISCLOSURE STATEMENT

: Masato Mitsuhashi

App. No.

10/796,298

Filed

March 9, 2004

For

DEVICE AND METHOD FOR HIGH-

THROUGHPUT QUANTIFICATION OF

MRNA FROM WHOLE BLOOD

Examiner

Unknown

Group Art Unit

1646

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing thirteen (13) references that are also enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

31 Aug. 2004

Daniel F. Altma

Registration No. 34,115

Attorney of Record

Customer No. 20,995

(949) 760-0404

H:\DOCS\CPP\CPP-1067.DOC 082004

	FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY, DOCKET NO. HITACHI.055CP2	APPLICATION NO. 10/796,298
101	PENFORMATION	DISCLOSURE STATEMENT		
SEP O 3	[4	Y APPLICANT	APPLICANT Masato Mitsuhashi	
	(USE SEVERAL SHEETS IF NECESSARY)	L SHEETS IF NECESSARY)	FILING DATE March 9, 2004	GROUP 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	5,707,526	1/13/98	Kraus et al.			

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)					
		Melanoma Research, Analysis of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction for tyrosinase and MART -1 after mononuclear cell collection with cell preparation tubes: a comparison with the whole blood guanidinium isothiocyanate RNA isolation method, Vol. 10 (2000), 119-126, T.J. de Vries, A. Fourkour C.J.A. Punt, D.J. Ruiter and G.N.P. van Muijen.				
		Proceedings of the National Academy of Sciences of the United States of America, <i>Diagnosis of Chronic Myeloid and Acute Lymphocytic Leukemias by Detection of Leukemia-Specific mRNA Sequences Amplified in vitro</i> , Vol. 85, No. 15 (Aug. 1, 1988), 5698-5702, Ernest S. Kawasaki, Steven S. Clark, Mazie Y. Coyne, Stephen D. Smith, Richard Champlin, Owen N. Witte, Frank P. McCormick.				
	4	Clinical Chemistry, Direct reverse transcription—PCR on oligo (dT)-immobilized polypropylene microplates after capturing total mRNA from crude cell lysates, 44:11 (Nov. 1, 1998), 2256-2263, Yohei Hamaguchi, Yoshimasa Aso, Hiroshi Shimada, and Masato Mitsuhashi.				
	5	Clinical Chemistry, <i>Quantitative Analysis of Tyrosinase Transcripts in Blood</i> , 46:7 (July 1, 2000), 921-927, Malin Johansson, Eva K. Pisa, Vuokko Tormanen, Kerstin Arstrand, Bertil Kagedal.				
		British Journal of Haematology, Expression of bcr-abl mRNA in individual chronic myelogenous leukaemia cells as determined by in situ amplification, 112 (March 1, 2001), 749-759, Katharina Pachmann, Shourong Zhao, Thomas Schenk, Hagop Kantarjian, Adel K. El-Naggar, Michael J. Siciliano, Jie-Qiang Guo, Ralph B. Arlingilaus and Michael Andreeff.				
		Clinical Chemistry, Quantitative Reverse Transcription-PCR Measurement of Thyroglobulin mRNA in Peripheral Blood of Healthy Subjects, 45:6 (June 1, 1999), 785-789, Susan T. Wingo, Matthew D. Ringel, Jeffrey S. Anderson, Aneeta D. Patel, Yvonne D. Lukes, Yin-Ying Djuh, Barbara Solomon, Diamaud Nicholson, Pina L. Balducci-Silano, Michael A. Levine, Gary L. Francis, R. Michael Tuttle.				
	8	Clinical Chemistry, Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors, 42:9 (Sept. 1996), 1369-1381, Timothy J. Pelkey, Henry F. Frierson Jr., David E. Bruns.				
	9	Journal of Clinical Microbiology, <i>Ultrasensitive Reverse Transcription-PCR Assay for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma,</i> (Oct. 1998), 2964-2969, Rita Sun, Joanne Ku, Harsha Jayakar, Jo-Ch Kuo, Donald Brambilla, Steven Herman, Maurice Rosenstraus, Joanne Spadoro.				
	10	RNAture Reagents for mRNA Isolation, Buffers, <april 2002,="" 24,="" at="" http:="" product_reagents.htm.<="" rnature.com="" td=""></april>				
		RNAture GenePlate® 96-well mRNA Isolation Kit, GenePlate®, <april 2002,="" 24,="" at="" http:="" product_geneplate.htm.<="" rnature.com="" td=""></april>				
	12	Pall Corporation, Pall Leukosorb® Medium, Fibrous Medium, <april 2002,="" 20610_4785.asp.<="" 24,="" at="" http:="" td="" www.pall.com=""></april>				
	13	Amplicor HIV-1 Monitor Test-Standard Method, August 1, 2000.				

H:\DOCS\CPP\CPP-1068.DOC/082004

EXAMINER	DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Case Docket No. HITACHI.055CP2

Date: August 31, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Masato Mitsuhashi

Appl. No.

10/796,298

Filed

March 9, 2004

For

DEVICE AND METHOD FOR

HIGH-THROUGHPUT

QUANTIFICATION OF MRNA

FROM WHOLE BLOOD

Examiner

Unknown

Group Art Unit:

1646

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 31, 2004

Daniel E. Altman, Reg. No. 34,115

TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with thirteen (13) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Daniel E. Altman

Registration No. 34,115

Attorney of Record Customer No. 20,995

(949) 760-0404